Ciclopirox

Spezifikationen

29342-05-0CAS-Nummer

249-577-2EG-Nummer

6-cyclohexyl-1-hydroxy-4-methylpyridin-2-oneIUPAC-Name

C12H17NO2Chemische Formel

207.27 g/molMolekulargewicht

CICLOPIROX; 29342-05-0; Loprox; Penlac; Ciclopiroxum; HOE 296b; 2(1H)-Pyridinone, 6-cyclohexyl-1-hydroxy-4-methyl-; cyclopirox; HOE-296b; 6-Cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridinone; 6-cyclohexyl-1-hydroxy-4-methylpyridin-2-one; Ciclodan; CNL8; 19W019ZDRJ; 2(1H)-Pyridone, 6-cyclohexyl-1-hydroxy-4-methyl-; 6-cyclohexyl-1-hydroxy-4-methyl-1,2-dihydropyridin-2-one; DTXSID9048564; CHEBI:453011; Dafnegin CSC; RefChem:58503; DTXCID2028193; D01AE14; G01AX12; 249-577-2; Ciclopiroxolamine; 6-cyclohexyl-1-hydroxy-4-methylpyridin-2(1H)-one; Ciclopiroxum [INN-Latin]; 6-Cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone; MFCD00599441; Loprox (TN); HOE296b; Terit; 6-cyclohexyl-1-hydroxy-4-methyl-pyridin-2-one; Ciclopirox gel; Loprox cream; Loprox Gel; Ciclopirox Olamin; Ciclopirox-Olamin; Stieprox; MLS002153867; Penlac (TN); Ciclopirox (USP/INN); SMR001233223; EINECS 249-577-2; UNII-19W019ZDRJ; Ciclopirox; 6-Cyclohexyl-1-hydroxy-4-methylpyridin-2(1H)-one; Ciclopirox CRS; Ciclopirox [USAN:USP:INN:BAN]; 29342-05-0 (free); Ciclopirox (Penlac); Ciclopirox (Standard); CICLOPIROX [MI]; CICLOPIROX [INN]; Prestwick0_000541; Prestwick1_000541; Prestwick2_000541; Prestwick3_000541; Spectrum2_000146; Spectrum3_000351; Spectrum4_000288; Spectrum5_000747; CICLOPIROX [USAN]; CICLOPIROX [VANDF]; CICLOPIROX [MART.]; CHEMBL1413; CICLOPIROX [USP-RS]; CICLOPIROX [WHO-DD]; SCHEMBL34424; BSPBio_000581; BSPBio_002041; KBioGR_000816; 6-Cyclohexyl-1-hydroxy-4-methyl-2-(1H)-pyridone; cid_38911; BIDD:GT0080; (6-Cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone); SPBio_000252; SPBio_002502; BPBio1_000641; orb1225410; orb1308516; CICLOPIROX [ORANGE BOOK]; Ciclopirox, >=98% (HPLC); SCHEMBL21816793; BDBM66087; GTPL11349; HY-B0450R; KBio3_001261; 6-CYCLOHEXYL-1-HYDROXY-4-METHYL-1H-PYRIDIN-2-ONE; CICLOPIROX [EP MONOGRAPH]; CICLOPIROX [USP MONOGRAPH]; GLXC-10499; HMS3656I12; HMS5081A19; HY-B0450; MSK15297; EBC-00572; s2528; AKOS015895717; AB06517; CCG-266632; DB01188; FC20430; KS-5085; NCGC00017112-04; NCGC00017112-05; NCGC00017112-06; NCGC00017112-08; NCGC00017112-11; NCGC00017112-22; NCGC00178850-01; NCGC00178850-02; AC-24195; SY102316; SBI-0206690.P002; DB-047566; 1-hydroxy-4-methyl-6-cyclohexyl-2-pyridone; NS00010120; SW196923-5; D03488; EN300-197928; AB00053438_09; AB00053438_10; AB00053438_11; F516562; Q419468; SR-05000001589-5; 6-Cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridinone #; BRD-K13044802-001-02-4; BRD-K13044802-001-03-2; BRD-K13044802-213-04-1; BRD-K13044802-213-09-0; BRD-K13044802-213-20-7; BRD-K13044802-213-21-5; BRD-K13044802-213-24-9; BRD-K13044802-213-25-6; Z1509504366; 2-aminoethanol;6-cyclohexyl-1-hydroxy-4-methyl-2-pyridone; Ciclopirox, European Pharmacopoeia (EP) Reference Standard; 2-aminoethanol;6-cyclohexyl-1-hydroxy-4-methyl-2-pyridinone; 2-azanylethanol;6-cyclohexyl-4-methyl-1-oxidanyl-pyridin-2-one; Ciclopirox, United States Pharmacopeia (USP) Reference StandardSynonyme